| Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus |
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus. |
zacks.com |
2025-05-14 16:45:36 |
Czytaj oryginał (ang.) |
| Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates |
Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago. |
zacks.com |
2025-05-13 22:20:43 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates |
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector |
I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determine if the market's lack of interest is justified or a broader cell therapy sector issue. The article explores FATE's pipeline updates, financial overview, and strengths and risks to provide a comprehensive investment thesis. |
seekingalpha.com |
2025-05-08 22:22:50 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. |
globenewswire.com |
2025-05-02 20:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting |
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications |
globenewswire.com |
2025-04-29 13:25:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag |
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus. |
zacks.com |
2025-04-15 15:45:34 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) |
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process |
globenewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. |
globenewswire.com |
2025-04-02 20:01:00 |
Czytaj oryginał (ang.) |
| FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus |
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus. |
zacks.com |
2025-03-06 12:06:14 |
Czytaj oryginał (ang.) |
| Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates |
Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2025-03-05 20:10:24 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE |
globenewswire.com |
2025-03-05 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. |
globenewswire.com |
2025-03-04 18:01:00 |
Czytaj oryginał (ang.) |
| Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know |
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-17 13:06:25 |
Czytaj oryginał (ang.) |
| Fate Therapeutics to Present at Upcoming Investor Conferences |
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-02-14 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap |
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. |
seekingalpha.com |
2025-02-04 21:41:27 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 3, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 35,000 shares of the Company's common stock at an exercise price per share of $1.27, which was the closing price per share of the Company's common stock as reported by NASDAQ on February 3, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 20,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. |
globenewswire.com |
2025-02-04 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company's common stock at an exercise price per share of $1.79, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 3,200 shares of its common stock to one newly-hired non-executive employee. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employees being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. |
globenewswire.com |
2025-01-03 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? |
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:29 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus |
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile |
globenewswire.com |
2024-12-09 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on December 2, 2024 the Company granted restricted stock units (RSUs) representing 18,600 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. |
globenewswire.com |
2024-12-03 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Announces Leadership Transition |
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. |
globenewswire.com |
2024-11-29 15:05:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics to Present at Upcoming December Investor Conferences |
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options |
Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. |
seekingalpha.com |
2024-11-20 18:34:16 |
Czytaj oryginał (ang.) |
| FATE Presents Encourgaing Data From Lupus Study, Stock Gains |
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study. |
zacks.com |
2024-11-19 16:55:34 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence |
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies |
globenewswire.com |
2024-11-18 10:05:00 |
Czytaj oryginał (ang.) |
| FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus |
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus. |
zacks.com |
2024-11-13 14:21:14 |
Czytaj oryginał (ang.) |
| Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates |
Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-11-12 20:21:15 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates |
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting |
Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies |
globenewswire.com |
2024-11-09 15:30:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting |
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation |
globenewswire.com |
2024-11-08 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2024 the Company granted restricted stock units (RSUs) representing 20,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. |
globenewswire.com |
2024-11-04 18:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. |
globenewswire.com |
2024-10-02 20:01:00 |
Czytaj oryginał (ang.) |
| Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference |
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York. |
globenewswire.com |
2024-09-12 20:01:00 |
Czytaj oryginał (ang.) |
| Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? |
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-12 16:30:36 |
Czytaj oryginał (ang.) |
| All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy |
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-16 17:00:34 |
Czytaj oryginał (ang.) |
| FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow |
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024. |
zacks.com |
2024-08-14 15:11:06 |
Czytaj oryginał (ang.) |